BRPI0612112A8 - composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1. - Google Patents

composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.

Info

Publication number
BRPI0612112A8
BRPI0612112A8 BRPI0612112A BRPI0612112A BRPI0612112A8 BR PI0612112 A8 BRPI0612112 A8 BR PI0612112A8 BR PI0612112 A BRPI0612112 A BR PI0612112A BR PI0612112 A BRPI0612112 A BR PI0612112A BR PI0612112 A8 BRPI0612112 A8 BR PI0612112A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
ccr1
mediated diseases
conditions
Prior art date
Application number
BRPI0612112A
Other languages
English (en)
Inventor
M K Pennell Andrew
J Kim Wright John
Li Lianfa
R Leleti Manmohan
Zhang Penglie
Chen Wei
Li Yandong
Xu Yuan
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37595833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0612112(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BRPI0612112A2 publication Critical patent/BRPI0612112A2/pt
Publication of BRPI0612112A8 publication Critical patent/BRPI0612112A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

composto, composição farmacêutica, e, uso de um composto. são fornecidos compostos que atuam como antagonistas potentes do receptor ccrl e têm atividade antiinflamatória in vivo. os compostos são geralmente derivados de aril piperazina e são úteis nas composições farmacêuticas, métodos para o tratamento de doenças mediadas por ccr1 e como controles dos ensaios para a identificação de antagonistas ccr1 competitivos.
BRPI0612112A 2005-06-22 2006-06-22 composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1. BRPI0612112A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69352505P 2005-06-22 2005-06-22
US60/693,525 2005-06-22
PCT/US2006/024313 WO2007002293A2 (en) 2005-06-22 2006-06-22 Azaindazole compounds and methods of use

Publications (2)

Publication Number Publication Date
BRPI0612112A2 BRPI0612112A2 (pt) 2010-10-19
BRPI0612112A8 true BRPI0612112A8 (pt) 2017-12-26

Family

ID=37595833

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612112A BRPI0612112A8 (pt) 2005-06-22 2006-06-22 composto, composição farmacêutica, e, método de tratar doenças ou condições mediadas por ccr1.

Country Status (26)

Country Link
US (2) US20070010523A1 (pt)
EP (1) EP1906965B1 (pt)
JP (1) JP5275794B2 (pt)
KR (2) KR20140026644A (pt)
CN (1) CN101242839B (pt)
AU (1) AU2006262122B2 (pt)
BR (1) BRPI0612112A8 (pt)
CA (1) CA2612552C (pt)
DK (1) DK1906965T3 (pt)
EA (1) EA017278B9 (pt)
ES (1) ES2543714T3 (pt)
HR (1) HRP20150832T1 (pt)
HU (1) HUE025476T2 (pt)
IL (1) IL188050A (pt)
MA (1) MA29568B1 (pt)
MX (1) MX2007015917A (pt)
NO (1) NO340621B1 (pt)
NZ (1) NZ564258A (pt)
PL (1) PL1906965T3 (pt)
PT (1) PT1906965E (pt)
RS (1) RS54206B1 (pt)
SG (2) SG162807A1 (pt)
SI (1) SI1906965T1 (pt)
UA (1) UA95777C2 (pt)
WO (2) WO2007002293A2 (pt)
ZA (2) ZA200800309B (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20090252779A1 (en) * 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
EP2155712B1 (en) * 2007-05-22 2016-09-07 ChemoCentryx, Inc. 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
JP5411927B2 (ja) 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１アンタゴニストとしてのピラゾール化合物
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN102159213B (zh) 2008-09-11 2015-05-27 凯莫森特里克斯股份有限公司 4-氨基-3-(咪唑基)-吡唑并[3,4-b]嘧啶
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
PE20110854A1 (es) * 2008-09-26 2011-12-23 Boehringer Ingelheim Int DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2742306A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
BR112012002130A2 (pt) * 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
AP2012006204A0 (en) * 2009-10-21 2012-04-30 Boehringer Ingelheim Int Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists.
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3181133B1 (en) 2010-12-20 2019-07-24 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
GB2488752A (en) * 2011-02-21 2012-09-12 Sony Dadc Austria Ag Microfluidic Device
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
CN103889983B (zh) 2011-09-14 2015-12-09 普罗克西梅根有限公司 酶抑制剂化合物
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2928474B1 (en) * 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TR201807959T4 (tr) 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105801574A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种1H-吡唑并[3,4-b]吡啶化合物的制备方法
RS58349B1 (sr) 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
IL261998B2 (en) * 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
CN108570049A (zh) * 2018-07-24 2018-09-25 上海毕得医药科技有限公司 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
JP7667097B2 (ja) * 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
CN110343103A (zh) * 2019-07-04 2019-10-18 深圳市格物致欣化学技术有限公司 吡唑并吡啶类化合物及其制备方法
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CN116375701A (zh) * 2022-03-11 2023-07-04 深圳微芯生物科技股份有限公司 一类双环杂环化合物、其制备方法及其应用
AR129722A1 (es) * 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5484575A (en) 1977-10-26 1979-07-05 Wellcome Found Imidazoline compound*its manufacture and insecticide composition
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4927942A (en) 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
EP1309593B1 (en) * 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
EP1438298B1 (en) * 2001-10-22 2010-01-27 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) * 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use

Also Published As

Publication number Publication date
WO2007002293A2 (en) 2007-01-04
JP5275794B2 (ja) 2013-08-28
NO20080408L (no) 2008-03-25
US20070010524A1 (en) 2007-01-11
RS54206B1 (sr) 2015-12-31
PT1906965E (pt) 2015-09-03
US20070010523A1 (en) 2007-01-11
HRP20150832T1 (hr) 2015-09-25
NZ564258A (en) 2011-02-25
IL188050A0 (en) 2008-03-20
CA2612552C (en) 2015-03-24
UA95777C2 (en) 2011-09-12
WO2007002667A2 (en) 2007-01-04
EA200800100A1 (ru) 2008-06-30
KR20140026644A (ko) 2014-03-05
KR101418024B1 (ko) 2014-07-16
HUE025476T2 (en) 2016-02-29
CN101242839B (zh) 2012-11-07
SG162807A1 (en) 2010-07-29
ZA200800309B (en) 2009-10-28
CN101242839A (zh) 2008-08-13
CA2612552A1 (en) 2007-01-04
NO340621B1 (no) 2017-05-15
SG10201504801VA (en) 2015-07-30
PL1906965T3 (pl) 2015-10-30
AU2006262122A1 (en) 2007-01-04
AU2006262122B2 (en) 2013-01-17
EA017278B9 (ru) 2013-01-30
US7524845B2 (en) 2009-04-28
MA29568B1 (fr) 2008-06-02
MX2007015917A (es) 2008-03-10
JP2008546794A (ja) 2008-12-25
IL188050A (en) 2015-10-29
EA017278B1 (ru) 2012-11-30
WO2007002667A3 (en) 2007-05-10
SI1906965T1 (sl) 2015-09-30
KR20080039850A (ko) 2008-05-07
DK1906965T3 (en) 2015-08-03
HK1124241A1 (en) 2009-07-10
EP1906965B1 (en) 2015-05-06
WO2007002293A3 (en) 2007-03-08
EP1906965A4 (en) 2011-05-18
EP1906965A2 (en) 2008-04-09
BRPI0612112A2 (pt) 2010-10-19
ZA200901845B (en) 2011-03-30
ES2543714T3 (es) 2015-08-21

Similar Documents

Publication Publication Date Title
WO2007002667A3 (en) Azaindazole compounds and methods of use
EP2155203A4 (en) Azaindazole compounds and methods of use
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
DK1531822T3 (da) 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
BRPI0811849A8 (pt) composto, composição farmacêutica, e, métodos para preparar o composto e para tratar doenças ou condições mediadas por ccr1
WO2007044804A3 (en) Piperidine derivatives and methods of use
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
SV2008002365A (es) Compuestos de quinolina heteroaromaticos ref. pc32593a
BR112015012842A2 (pt) diazol lactamas
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI1009252A2 (pt) composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
NO20091052L (no) Diaryleterderivater og anvendelser derav
BRPI0513713A (pt) derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BRPI0615163A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
BRPI0510024A (pt) compostos e composições como modulares de ppar
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements